Optimvia
Cincinnati, US · Founded 2016 · Ohio LLC
Optimvia engineers proteins to create new therapeutic products, focusing on designing enzymes and enzyme systems for biosynthetic manufacturing of critical medicines like heparin. The company uses its proprietary ADEPT Platform to computationally design novel proteins for pharmaceutical applications.
Founders & leadership
KM
Keith M. KleemanCEO and Chair of the Board
JT
John T. GlassChairman of the Board of Managers, Treasurer and Secretary
TF
Tarsis FerreiraManager and Chief Scientific Officer
Board
MK
Mickey KowitzBoard director
SG
Steve GeisBoard director
JR
James RothmanBoard director
JE
James E. Rothman, PhD
SG
Steve Geis, PhD MDBoard director
Reported raises · per SEC filings
Form D private placements$598.2K disclosed across 2 of 4 rounds · 2017–2026
▶$75KraisedApr 2026 · 2 investors · Other Health CareRule 506(b)
▶$75KraisedApr 2026 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Keith KleemanDirector, Executive Officer
- Steve GeisDirector
- Mickey KowitzDirector
- James RothmanDirector
- Offering amount
- $500K
- Amount sold
- $75K
- First sale
- Mar 2026
- Incorporated
- Limited Liability Company, Ohio
- Federal exemptions
- 06b
▶$523.2KraisedAug 2024 · 8 investors · Other Health CareRule 506(b)
▶$523.2KraisedAug 2024 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mickey KowitzDirector
- Keith M. KleemanDirector, Executive Officer
- Steve GeisDirector
- James RothmanDirector
- Offering amount
- $5M
- Amount sold
- $523.2K
- First sale
- Aug 2023
- Incorporated
- Limited Liability Company, Ohio
- Federal exemptions
- 06b
▶$5MofferedJan 2021 · Other Health CareRule 506(b)
▶$5MofferedJan 2021 · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Steve GeisDirector
- Mickey KowitzDirector
- James RothmanDirector
- Tarsis FerreiraExecutive Officer
- John GlassPromoter
- Keith M. KleemanExecutive Officer, Director
- Offering amount
- $5M
- Minimum investment
- $25K
- Proceeds to insiders
- $125K
- Incorporated
- Limited Liability Company, Ohio, 2017
- Federal exemptions
- 06b
▶$2.4MofferedMay 2017 · BiotechnologyRule 506(b)
▶$2.4MofferedMay 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John T. GlassExecutive Officer, Director, Promoter
- Tarsis FerreiraExecutive Officer, Director, Promoter
- Keith M. KleemanExecutive Officer, Director, Promoter
- Offering amount
- $2.4M
- Minimum investment
- $25K
- Incorporated
- Limited Liability Company, Ohio, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Attovia Therapeutics8 shared keywordsAttovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.
IQVIA5 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Solu4 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Optimvia for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Optimvia do?
- Optimvia engineers proteins to create new therapeutic products, focusing on designing enzymes and enzyme systems for biosynthetic manufacturing of critical medicines like heparin. The company uses its proprietary ADEPT Platform to computationally design novel proteins for pharmaceutical applications.
- How much funding has Optimvia raised?
- Optimvia has disclosed $598.2K raised across 2 of its 4 known rounds.
- Where is Optimvia headquartered?
- Optimvia is headquartered in Cincinnati, US.